Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

Despite major therapeutic progress, most advanced solid tumors are still incurable. Cancer
interception is the active way to combat cancer onset, and development of this approach …

Background Choosing the specimen type is the first step of the pre-analytical process.
Previous reports suggested plasma as the optimal specimen for circulating tumor DNA …

Background Differences in cell‐free DNA (cfDNA) fragments have been described as a
valuable tool to distinguish cancer patients from healthy individuals. We aim to investigate …

One in every four deaths is due to cancer in Europe. In view of its increasing incidence,
cancer became the leading cause of death and disease burden in Denmark, France, the …

Cell-free DNA (cfDNA) is present in numerous body fluids and generally blood cells. It is
undoubtedly the utmost promising tool among all components of liquid biopsy. Liquid biopsy …

Liquid biopsy is a broad term that refers to the testing of body fluids for biomarkers that
correlate with a pathological condition. While a variety of body-fluid components (eg …

Tumor-associated cell-free DNAs (cfDNAs) are found to play some important roles at
different stages of tumor progression; they are involved in the transformation of normal cells …

Simple Summary The circulating cancer biomarkers, known as 'liquid biopsy'(LB), represent
a means to profile tumors non-invasively and collect information that can define therapeutic …